Keros Therapeutics, Inc. announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. Charles Newton served as the Chief Financial Officer of Lyell Immunopharma, Inc. from February 2021 until his retirement from Lyell in September 2025. Prior to Lyell, he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas at Bank of America.
Earlier in his career, he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, Managing Director and Head of Western Region Healthcare Investment Banking at Morgan Stanley and as a Corporate Finance Analyst at Lehman Brothers. Charles Newton currently serves as a board member at Novavax, Inc. and Coherus Oncology, Inc. and previously served on the board of directors of 2seventy bio, Inc. until their acquisition by Bristol Myers Squibb, and Carmot Therapeutics, until their acquisition by Roche. Charles Newton holds a B.S. in Finance from Miami University and an M.B.A. from The Tuck School at Dartmouth College.
Concurrent with Charles Newton joining Keros? Board of Directors, the Company also announced that Carl Gordon, Ph.D., CFA, will be stepping down as a director of the Company, effective March 9, 2026. Following Dr. Gordon?s resignation from the Board, including from the Compensation Committee, and Mr. Newton?s appointment to the Compensation and Audit Committees, the membership of the three standing committees of the Board is as follows: Audit Committee: Mary Ann Gray (chair), Nima Farzan, Julius Knowles, Charles Newton.
Compensation Committee: Alpna Seth (chair), Nima Farzan, Mary Ann Gray, Charles Newton. Nominating and Corporate Governance Committee: Jean-Jacques Bienaimé (chair), Julius Knowles, Alpna Seth.
